[PDF][PDF] Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives
JP Arab, SJ Karpen, PA Dawson, M Arrese… - …, 2017 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …
The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp
…, M Makishima, DJ Mangelsdorf, SJ Karpen - Gastroenterology, 2001 - Elsevier
Background & Aims: Hepatic bile acid homeostasis is regulated by negative feedback inhibition
of genes involved in the uptake and synthesis of bile acids. Bile acids down-regulate the …
of genes involved in the uptake and synthesis of bile acids. Bile acids down-regulate the …
Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and …
…, E Neimark, VL Ng, SJ Karpen - Journal of pediatric …, 2017 - journals.lww.com
Cholestatic jaundice in infancy affects approximately 1 in every 2500 term infants and is
infrequently recognized by primary providers in the setting of physiologic jaundice. Cholestatic …
infrequently recognized by primary providers in the setting of physiologic jaundice. Cholestatic …
[HTML][HTML] Intestinal transport and metabolism of bile acids
PA Dawson, SJ Karpen - Journal of lipid research, 2015 - ASBMB
In addition to their classical roles as detergents to aid in the process of digestion, bile acids
have been identified as important signaling molecules that function through various nuclear …
have been identified as important signaling molecules that function through various nuclear …
[HTML][HTML] Stigmasterol, a soy lipid–derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR
…, R Von Furstenberg, DD Moore, SJ Karpen - Pediatric …, 2007 - nature.com
Phytosterols, components of soy-derived lipids, are among the proposed exacerbants of
parenteral nutrition–associated cholestasis (PNAC). We investigated whether phytosterols …
parenteral nutrition–associated cholestasis (PNAC). We investigated whether phytosterols …
[PDF][PDF] Biliary atresia: clinical and research challenges for the twenty‐first century
Biliary atresia (BA) is a fibroinflammatory disease of the intrahepatic and extrahepatic biliary
tree. Surgical hepatic portoenterostomy (HPE) may restore bile drainage, but progression of …
tree. Surgical hepatic portoenterostomy (HPE) may restore bile drainage, but progression of …
Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors.
…, M Arrese, H Lee, JL Boyer, SJ Karpen - The Journal of …, 1998 - Am Soc Clin Investig
Sodium-dependent uptake of bile acids across the hepatic basolateral membrane is rapidly
and profoundly diminished during sepsis, thus contributing to the pathogenesis of sepsis-…
and profoundly diminished during sepsis, thus contributing to the pathogenesis of sepsis-…
The role of inflammation in cholestasis: clinical and basic aspects
A Kosters, SJ Karpen - Seminars in liver disease, 2010 - thieme-connect.com
Hepatobiliary transport systems are essential for the uptake and excretion of a variety of
compounds including bile acids. Disruption and dysregulation of this excretory pathway result in …
compounds including bile acids. Disruption and dysregulation of this excretory pathway result in …
Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition–associated liver disease
…, PM Vue, W Zhang, KDR Setchell, SJ Karpen… - Science translational …, 2013 - science.org
Parenteral nutrition–associated liver disease (PNALD) is a serious complication of PN in
infants who do not tolerate enteral feedings, especially those with acquired or congenital …
infants who do not tolerate enteral feedings, especially those with acquired or congenital …
[HTML][HTML] Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial
…, RHJ Houwen, BM Kamath, SJ Karpen… - The Lancet …, 2022 - thelancet.com
Background Progressive familial intrahepatic cholestasis (PFIC) is a group of inherited paediatric
liver diseases resulting from mutations in genes that impact bile secretion. We aimed to …
liver diseases resulting from mutations in genes that impact bile secretion. We aimed to …